Asma Abdul Razzak, Pervez Ashraf.
Preventing NASH with Empagliflozin and Linagliptin: a Diabetic Drug Combination.
J Bahria Uni Med Dental Coll Jan ;13(4):281-5.

Objective: To determine the effect of anti-diabetic drug combination of 25mg empagliflozin and 5mg linagliptin for the prevention of NASH. Study Design & Setting: Quasi-Experimental Study design, Department of Gastroenterology, Medicare Cardiac and General Hospital Karachi from October 2022 to March 2023. Methodology: This study was carried out after approval from the ethical board of the hospital. The selection criteria of patients included positive family history of obesity, hyperlipidemia/ hypertriglyceridemia, hypothyroidism, smoking and F3 Fibrosis on transient elastography. The initial screening of clinical history, physical examination, laboratory findings were recorded after taking the written consent from each patient. The baseline findings were recorded and the effect of drugs was examined after follow-up of six months. Results: The study included 150 patients who received the treatment of empagliflozin and linagliptin. The mean age of these patients was 37+-4.9 years. Majority of them were males 76% and 60% were diagnosed type 2 diabetes more than 5 years ago. Hyperglycemia and hypoglycemia were found in 16.7% in patients with headache of 26.7%. The baseline findings were significantly changed with effective and favorable results as p-value<0.001. Conclusion: The treatment with combine effect of the antidiabetic drugs empagliflozin (25 mg) and linagliptin (5 mg) showed a safety profile of preventing NASH with the fixed dose. It reduced the ALT and AST levels, reduced BMI, triglyceride level, HBA1C and the risk of progression of advance liver disease NASH. After taking antidiabetic drugs, Fibrosis was improved and it showed F1-F2 on transient elastography. Keywords: Anti-diabetic drugs, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com